Oncology Overview ASCO 2020 Forward-looking statement This - - PowerPoint PPT Presentation

▶
oncology overview
SMART_READER_LITE
LIVE PREVIEW

Oncology Overview ASCO 2020 Forward-looking statement This - - PowerPoint PPT Presentation

Aug 25, 2023 417 likes •613 views

Merck Oncology Overview ASCO 2020 Forward-looking statement This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company) includes forward-looking statements within the meaning of the safe harbor provisions of the

slide-1
SLIDE 1

Merck

Oncology Overview

ASCO 2020

slide-2
SLIDE 2

Forward-looking statement

2

This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

slide-3
SLIDE 3

We are executing on a broad oncology strategy to improve

  • utcomes for cancer patients globally

3

Further establish KEYTRUDA as foundational treatment and advance into earlier stages of disease Broadly explore combinations to reach more patients Advance pipeline and pursue strategic collaborations and acquisitions to expand portfolio Id Identi tify patients most likely to benefit using biomarkers

slide-4
SLIDE 4

KEYTRUDA has now demonstrated activity in more than 30 different types of cancer defined by site of origin, histology, or genetic markers

4

  • 100

100

  • 100

100

  • 100

100

  • 100

100

  • 100

100

  • 100

100

  • 100

100

NSC SCLC LC2

  • 100

100

Gastric ic6

  • 100

100

  • 100

100

H&N3 TNB TNBC5

  • 100

100

cHL HL7 Urot rotheli lial4 Change e From B Basel selin ine in in Tum umor S Siz ize, % %

  • 100

100

Mesot

  • theliom

ioma9

  • 100

100

An Anal al14

14

  • 100

100

  • 100

100

SC SCLC LC11

11

  • 100

100

NPC PC13

13

HC HCC16

16

Esop

  • phage

geal al12

12

  • 100

100

Ovari rian an10

10

  • 100

100

ER ER+/HE HER2– BC BC17

17

Cervi vica cal18

18

Thyroid

  • id19

19

Saliv ivary20 Endometria rial21

  • 100

100

Mela lano noma1

  • 100

100

Bi Biliar ary T Trac act15

15

  • 100

100

Pros rostate22 GBM GBM23

23

  • 100

100

  • 100

100

MSI SI-H C H CRC24

24

  • 100

100

  • 100

100

Carcinoid noid25

25

  • 100

100

pNET ET25

25

cc ccRCC27 nccR ccRCC28

28

  • 100

100

MSI SI-H non non-CRC RC24

24

  • 100

100

Merk rkel C l Cell26

  • 100

100

tTMB MB-H29

  • 100

100

cSC SCC30

  • 100

100

  • 100

100

NH NHL P PMBCL CL8

  • 1. Daud A et al. ASCO 2015; 2. Garon EB et al. ESMO 2014; 3. Seiwert T et al. ASCO 2015; 4. Plimack E et al. ASCO 2015; 5. Nanda R et al. SABCS 2014; 6. Bang YJ et al. ASCO 2015; 7. Moskowitz C et al. ASH 2014; 8. Zinzani PL et al.

ASH 2015; 9. Alley EA et al. AACR 2015; 10. Varga A et al. ASCO 2015; 11. Ott PA et al. 2015 ASCO; 12. Doi T et al. ASCO 2015; 13. Hsu C et al. ECC 2015; 14. Marabelle A et al. ASCO 2020; 15. Bang Y-J et al. ECC 2015; 16. Zhu A et al. ASCO 2018; 17. Rugo HS et al. SABCS 2015; 18. Frenel JS et al. ASCO 2016; 19. Mehnert JM et al. ASCO 2016; 20. Cohen R et al. ASCO 2016; 21. Ott PA et al. ASCO 2016; 22. Hansen AR et al. ESMO 2016; 23. Reardon D et al. SNO 2016; 24. Diaz L et al. ESMO 2017; 25. Mehnert J et al. ESMO 2017; 26. Nghiem P et al. ASCO 2018; 27. McDermott DF et al. ASCO 2018; 28. McDermott DF et al. ASCO-GU 2019; 29. Marabelle A et al. ESMO 2019; 30. Grob JJ et al. ESMO 2019.

= ca cance cer t type pes wit ith ap h approved in indic icat atio ions

slide-5
SLIDE 5

KEYTRUDA monotherapy and in combination improves overall survival in Phase 3 studies across a broad range of malignancies

N o . a t R is k 5 1 0 1 5 2 0 2 5 3 0 3 5 4 0 4 5 5 0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 M o n t h s O S , % 2 57 1 97 1 52 1 10 70 2 55 2 07 1 31 89 40 91 59 43 21 21 9 13 5 1

2L+ NSCLC, T , TPS PS ≥50% 0% KEYN YNOT OTE-04 045 Pembro

  • vs

vs Chem emo 2L Bla ladder, A Any P y PD-L1 L1 KEYN YNOT OTE-02 024 Pembro

  • vs

vs Chemo

  • 1L NSCL

SCLC, T TPS ≥50% 0% KEYN YNOT OTE-18 181 Pembro

  • vs

vs Chem emo 1L Esophag hageal al, C CPS ≥10 10 KEYN YNOT OTE-04 048 Pembro

  • vs

vs EXTREM EME 1L HNSCC, CC, C CPS S ≥1

1 0 2 0 3 0 4 0 5 0 6 0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 M o n t h s O S , % N o . a t R is k 2 90 1 78 1 31 1 01 1 1 52 58 29 21 1 50 10 6 12 18 24 30 36 42 48 10 20 30 40 50 60 70 80 90 100 Months OS, %
  • No. at Risk
270 170 116 86 272 140 73 47 69 35 60 28 52 26 17 12 6 12 18 24 30 36 42 48 10 20 30 40 50 60 70 80 90 100 Months OS, %
  • No. at Risk
154 121 89 78 50 151 108 61 48 24 73 44 5 6 106 80 66 35 6 12 18 24 30 36 42 48 10 20 30 40 50 60 70 80 90 100 Months OS, %
  • No. at Risk
637 463 368 304 91 367 485 319 236 65 178 126 1 2 30 20 4 8 12 16 20 24 28 32 36 10 20 30 40 50 60 70 80 90 100 Months OS, %
  • No. at Risk
107 86 59 45 10 115 76 48 23 9 29 14 5 4 1 21 14 4 8 1 2 1 6 2 0 2 4 2 8 3 2 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 M o n t h s O S , % N o . a t R is k 2 78 2 37 1 90 1 10 1 35 1 13 84 42 1 52 65 57 23 16 8 1 1

KEYN YNOT OTE-240 40 Pembro

  • vs

vs Placebo bo 2L HCC, CC, Any Any PD-L1 L1

5 1 0 1 5 2 0 2 5 3 0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 M o n t h s O S , % N o . a t R is k 2 47 1 60 1 03 2 48 1 51 82 48 34 14 10 2 1

KEYN YNOT OTE-04 040 Pembro

  • vs

vs SO SOC C 2L+ HNSC SCC, Any Any PD-L1 L1 1L Gastric, C c, CPS ≥10 10 KEYN YNOT OTE-00 006 Pembro

  • vs

vs Ip Ipi Ip Ipi-Naive ve M Melanoma, A , Any P PD-L1 L1

10 20 30 40 50 60 10 20 30 40 50 60 70 80 90 100 Months OS, %
  • No. at Risk
556 416 317 264 278 158 111 94 47 19 233 85 208 75

OS OS OS OS OS OS OS OS OS OS OS OS OS OS

5 10 15 20 25 30 35 40 10 20 30 40 50 60 70 80 90 100 Months OS, %
  • No. at Risk
96 79 57 41 23 98 80 54 36 12 11 4 1 1 26 23

KEYN YNOT OTE-11 119 Pembro

  • vs

vs Chemo

  • 2/3L

3L T TNBC, C, CP CPS ≥10 10

OS OS OS OS OS OS

KEYN YNOT OTE-04 042 Pembro

  • vs

vs Chem emo 1L NSCL SCLC, T TPS ≥1% 1% KEYN YNOT OTE-01 010 Pembro

  • vs

vs Docet etaxel el

6 1 2 1 8 2 4 3 0 3 6 4 2 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 M o n t h s O S , % N o . a t R is k 92 62 52 90 70 42 45 28 32 16 13 7 4

OS OS

KEYN YNOT OTE-06 062 Pembro

  • vs

vs Chemo

  • KEYN

YNOT OTE-18 189 Pemb mbro + + Peme metrexed/Platinum m vs vs Placeb ebo + + Pemet etrexed ed/Platinum 1L Nonsquamous N NSCL SCLC, Any Any P PD-L1 L1

3 6 9 1 2 1 5 1 8 2 1 2 4 2 7 3 0 3 3 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 M o n t h s O S , % N o . a t R is k 4 10 3 77 3 46 2 56 79 2 06 1 83 1 49 82 26 2 34 72 28 10 3 16 1 15 2 83 99 1 44 45 2

OS OS

6 12 18 24 30 10 20 30 40 50 60 70 80 90 100 Months OS, %
  • No. at Risk
228 175 60 225 170 44 102 89 15 8 1

KEYN YNOT OTE-60 604 Pembro + + EP EP vs vs Pla lacebo + + EP EP 1L SCL SCLC, Any Any P PD-L1 L1

OS OS

KEYN YNOT OTE-40 407 Pembr bro + + Carbo boplatin/ n/Taxane vs vs Plac acebo + + Carboplati atin/Taxane 1L Sq Squamous N NSCL SCLC, Any Any P PD-L1 L1

3 6 9 1 2 1 5 1 8 2 1 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 M o n t h s O S , % N o . a t R is k 2 78 2 56 1 88 1 24 17 2 81 2 46 1 75 93 16 62 45 2 4

OS OS

KEYN YNOT OTE-42 426 Pembr bro + + Axitini nib b vs vs Sunitin inib ib 1L RCC, CC, A Any P PD-L1 L1

4 8 1 2 1 6 2 0 2 4 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 M o n t h s O S , % N o . a t R is k 4 32 4 17 3 78 2 56 18 4 29 4 01 3 41 2 11 20 1 36 1 10

OS OS

KEYN YNOT OTE-04 048 Pembr bro + + Platinu num vs vs EXTREM EME 1L HNSC SCC, Any Any P PD-L1 L1

5 1 0 1 5 2 0 2 5 3 0 3 5 4 0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 1 0 0 M o n t h s O S , % N o . a t R is k 2 81 2 27 1 69 1 22 40 2 78 2 27 1 47 1 00 20 75 51 10 5 1 1

OS OS

Monoth therap rapy Combi bina nations ns

5

slide-6
SLIDE 6

6

Comprehensive KEYTRUDA development program

>1, >1,200 200

Ong Ongoing g cl clin inical tria trials Registr istratio ional tria trials u s under w way

>9 >90

Combin inatio ion tria trials

>8 >800 00

Tria rials in s in adj adjuvan ant / / neoadj

  • adjuvant

and nd ea earli lier er li line nes

>110 110

slide-7
SLIDE 7

ASCO 2020: Continued flow of data from deep & diverse oncology portfolio

New Phase 3 data for KEYTRUDA in TNBC, MSI-H CRC and cHL New Phase 2 data for KEYTRUDA in Stage III NSCLC

Demonstrating KEYTRUDA’s long-term survival benefits

Long-term survival data for KEYTRUDA in NSCLC, RCC and Melanoma

Progressing novel mechanisms

New Phase 2 data from our oral HIF- 2α inhibitor in VHL RCC MK-6482 now in Phase 3 in 2L RCC

Presenting new KEYTRUDA data

7

slide-8
SLIDE 8

KEYNOTE-355: Improved efficacy and supportive

  • f overall TNBC development program

8

KE KEYTRU TRUDA DA p plus lus chemo chemo redu duced d th the r risk isk of dise

  • f disease

se pro rogres gression n or r deat eath h by by 35% 5% vs. chemo chemo for cert r certai ain n TNB NBC pa patie tients ts (H (HR = 0 = 0.65 65 [95% [95% CI, CI, 0.49 49-0.8 .86], ], p=0.0 .001 012) 2) Tri Trial al co cont ntinues es f for r OS OS

Data cutoff: Dec. 11, 2019

Pro rogre ressi ssion-Free S Survi vival al: P PD-L1 C CPS PS > 10 10

slide-9
SLIDE 9

KEYNOTE-177: Single-agent KEYTRUDA may become new standard of care in 1L MSI-H mCRC patients

9

Median (95% CI) 16.5 mo (5.4-32.4) 8.2 mo (6.1-10.2)

4 8 12 16 20 24 28 32 36 40 44 48 10 20 30 40 50 60 70 80 90 100

Time, months PFS, %

  • No. at Risk

153 96 77 72 64 60 55 37 20 7 5 154 100 68 43 33 22 18 11 4 3

12-mo rate 55% 37% 24-mo rate 48% 19%

KE KEYTRU TRUDA DA mo mono notherap herapy sig signific ificantl tly redu duced r d risk of isk of dise disease se pr prog

  • gression

ssion or

  • r

deat eath by h by 40% and and mo more re than d han doubled bled med median PFS an PFS vers ersus us chemo chemo (HR HR = = 0.60 60 [95% [95% CI, CI, 0.45 45-0.8 .80], 0], p=0.0 .000 002) 2) Tri Trial al co cont ntinues es f for r OS OS

Data cutoff: Feb. 19, 2020

slide-10
SLIDE 10

KEYNOTE-204: Displacing standard of care in 2L+ relapsed refractory classic Hodgkin’s lymphoma

10

KE KEYTRU TRUDA DA mo mono notherap herapy sh show

  • wed sta

d statistic tistically signi gnificant and and cli clini nically lly meani meaningful imp mpro rovement ement in n PFS v PFS vers ersus BV BV in n R/R R/R cHL cHL (HR HR = = 0.65 65 [95 [95% CI, CI, 0.48 .48-0.8 .88], p ], p=0.00271) .00271) Tri Trial al co cont ntinues es f for r OS OS

Data cutoff: Jan. 16, 2020

slide-11
SLIDE 11

Long-term follow-up data confirm durable overall survival benefits with KEYTRUDA used in combination or as an adjuvant following surgery

11

+XX% YOY

NSCLC RCC Melanoma

In the final analysis of KEYNOTE-189, KEYTRUDA in combination with chemotherapy reduced the risk of death by 44% versus chemotherapy and at two years, demonstrated a sustained, long-term survival benefit in metastatic NSCLC. An updated analysis from KEYNOTE-426 showed the combination of KEYTRUDA plus axitinib continued to demonstrate durable anti-tumor activity vs. sunitinib. In a 3-yr follow-up on KEYNOTE-054, KEYTRUDA as adjuvant therapy, provided, a sustained improvement in RFS, which was clinically meaningful, in resected high- risk stage III melanoma.

slide-12
SLIDE 12

12

VHL disease is a multi-system disease with most patients having several different tumors Data demonstrates the therapeutic potential for MK-6482 (HIF-2α) in VHL-associated ccRCC patients, where there is a high unmet need

  • 27.9% ORR and 86.9% of patients saw a decrease in

target lesion size Beyond patients with VHL disease, Phase 2 data presented in 2019 demonstrated the potential as monotherapy for treatment of advanced or metastatic RCC, particularly in PD-1/PD-L1 refractory patients with 24% partial responses (PR) and 54% stable disease (SD) Phase 3 trial under way studying MK-6482 vs. everolimus in patients with advanced 2L RCC who have progressed following treatment with PD-1/PD-L1 combined with VEGF targeted therapy

MK-6482: First-time data shows promising overall response rate

in Von-Hippel Lindau (VHL)-associated kidney cancer patients

Benign Tumors

  • CNS Hemangioblastoma (70-80%)
  • Retinal Hemangioblastoma (50-60%)
  • Pancreatic Cyst and Cystadenoma (50%)
  • Endolymphatic Sac Tumor
  • f the middle ear (10-25%)
  • Tumor of the Epididymis or Broad

Ligament (10-60%)

Areas of the Body Affected by von Hippel-Lindau Disease

Advanced/Malignant Tumors

  • RCC (25-60%)
  • Pheochromocytoma (10-20%)
  • Pancreatic NET (10-20%)
slide-13
SLIDE 13

KEYTRUDA is being explored in a broad adjuvant program with 20 registrational studies ongoing

2018 2018 2019 2019 202 2020 202 2021 202 2022 202 023 202 024 202 025 202 026+ 6+

Adjuvant Melanoma (KEYNOTE-054) APPR PPROVE VED TNBC Neoadjuvant / Adjuvant (KEYNOTE-522) pCR p pres esen ented ed cSCC Locally Advanced (KEYNOTE-629) PDUF DUFA: JUNE JUNE 2 29 HNSCC Adjuvant (KEYNOTE-412) NSCLC Adjuvant (KEYNOTE-091) Adjuvant Melanoma (KEYNOTE-716) RCC Adjuvant (KEYNOTE-564) Gastric & Esophageal Adjuvant / Neoadjuvant (KEYNOTE-585) HNSCC Adjuvant / Neoadjuvant (KEYNOTE-689) NSCLC Neoadjuvant (KEYNOTE-671) Neo/adjuvant MIBC (KEYNOTE-866) Neo/adjuvant MIBC (KEYNOTE-905) NSCLC Stage I/IIa (KEYNOTE-867) HCC Adjuvant (KEYNOTE-937) Ovarian BRCAwt + chemo (KEYLYNK-001) TNBC Adjuvant (KEYNOTE-242) cSCC Locally Advanced (KEYNOTE-630) ER+ / HER2- Breast Cancer Adjuvant / Neoadjuvant (KEYNOTE-756)

Timeline based on clinicaltrial.gov primary completion dates. Actual timing may vary.

13

slide-14
SLIDE 14

Extensive KEYTRUDA+LYNPARZA combination (KEYLYNK) and LYNPARZA monotherapy programs

  • 1L, nonBRCA, KEYTRUDA combo (KEYLYNK-001)
  • 1L Maintenance BRCA+ (SOLO-1) - Approved
  • 1L Maintenance, All Comers Combo + Bev (PAOLA-1) - Approved
  • PSR, All Comers Combo + Cediranib (GY004)
  • PRR, All Comers Combo + Cediranib (GY005)
  • 2L+ PSR (SOLO2/Study19 ) - Approved
  • 3L+ PSR, gBRCA Treatment (SOLO3)
  • TNBC (KEYLYNK-009)
  • mBC, gBRCA (OlympiAD) - Approved
  • HER2- Adjuvant, gBRCAm (OlympiA)
  • 1L Maintenance gBRCA

(POLO) - Approved

  • mCRPC, All Comers (KEYLYNK-010)
  • mCRPC, HRRm (PROfound) - Approved
  • mCRPC, All Comers Combo + Abiraterone

(PROpel)

  • 1L NSQ NSCLC (KEYLYNK-006)
  • 1L SQ NSCLC (KEYLYNK-008)
  • Stage III NSCLC (KEYLYNK-012)
  • HRRm/HRD Basket (KEYLYNK-007)
  • HRRm Basket (LYNK-002)

Lung Cancer Tumor Agnostic

Ovarian cancer Breast cancer Pancreatic cancer Prostate cancer Lung cancer Tumor agnostic

PRR: Platinum Relapsed Recurrent; PSR: Platinum Sensitive Recurrent Collaboration with AstraZeneca

14

slide-15
SLIDE 15

Extensive KEYTRUDA+LENVIMA combination (LEAP) and LENVIMA monotherapy programs

  • 1L RCC Combo with Evero or

KEYTRUDA (KN-581 / Study 307)

  • 2L RCC Combo with Evero

(Study 205) - Approved

  • 1L EC (LEAP-001)
  • 2L EC (Study 309 / KN-775)
  • 2L EC (KEYNOTE-146) -

Approved

  • 1L HCC Combo (LEAP-002)
  • 1L HCC Combo/TACE (LEAP-012)
  • 1L HCC Mono (Study 304) – Approved
  • 1L Melanoma (LEAP-003)
  • 2L Melanoma (LEAP-004)
  • 1L UC (LEAP-011)
  • 1L PD-L1+ HNSCC

(LEAP- 010)

  • TNBC
  • Gastric
  • Ovarian
  • Colorectal
  • Glioblastoma
  • Biliary
  • 1L NSQ Combo with KEYTRUDA

and Chemo (LEAP-006)

  • 1L PD-L1+ NSCLC (LEAP-007)
  • 2L NSQ (LEAP-008)
  • 1L Thyroid -

Approved

Endometrial carcinoma Hepatocellular carcinoma Melanoma Renal cell carcinoma Thyroid cancer Lung cancer Urothelial cancer Head & neck cancer Basket trial

Registrational studies only Collaboration with Eisai

15

slide-16
SLIDE 16

16

Early oncology pipeline* includes more than 20 investigational immuno-therapeutic candidates – including novel combinations with KEYTRUDA

Personalized Cancer Vaccines Tumor Microenvironment Modulators

Therapeutic vaccines based on patients’ specific cancer could potentially prime the immune system to recognize certain characteristics and attack the cancer cells Regulating the environment around tumors, including through oncolytic viruses, may influence tumor growth and its interaction with the immune system Phase 1 Phase 2

Immune Agonists

Molecules designed to stimulate immune system functions, such as enhancing the activity of anti-tumor immune cells

RIG-I receptor (MK-4621) CD-27 agonist (MK-5890) STING agonist (MK-1454)

Phase 1/2

Inhibition of Negative Immune Regulators

Blocking the action of molecules that suppress the immune system may trigger a more robust anti-tumor response

ILT4 antagonist (MK-4830) LAG3 (MK-4280) CTLA4 (MK-1308) TIGIT (MK-7684) RNA-based vaccine

(Moderna)

(V940 / mRNA-4157) CDK 1, 2, 5, 9 (MK-7965) V937 oncolytic virus (formerly CAVATAK) BTK Inhibitor (MK-1026) AKT Inhibitors (MK-7075 & MK-4440)

Pre-Clinical

TGFβ (Tilos Therapeutics) KRAS (Moderna) (V941 / mRNA-5671) KRAS – Taiho/Astex *Select compounds only ERK Inhibitor (MK-8353) HIF-2α Inhibitor (MK-6482)

slide-17
SLIDE 17

We have pursued collaborations, licensing agreements, and acquisitions that will increase our ability to provide benefit to cancer patients

17

Development Stage Development Program Kinase inhibitory discovery and development for treatment

  • f patients with cancer and other diseases

Portfolio of investigational antibodies modulating TGFβ complex for the treatment of cancer, fibrosis and autoimmune disease Development of novel small molecule therapeutic candidates targeting HIF-2α for the treatment of patients with cancer and other diseases Collaboration for the development of small molecule inhibitors against several drug targets, including the KRAS oncogene Gain access to an investigational intratumoral and intravenous formulation

  • f the Coxsackievirus Type A21, designed to infect and kill cancer cells

Phase 2 in CLL Preclinical Phase 3 in RCC Preclinical Phase 2 in melanoma Acquisition

slide-18
SLIDE 18

Creating long-term value for patients, employees and shareholders

Anchored by our deep bench of talent, commitment to our mission & focus on breakthrough science and innovation

Next 5 Years

Strong execution driving sustainable revenue growth, meaningful margin expansion and accelerated bottom-line growth

5-10 Years

Rich pipeline addressing areas of high unmet need to drive performance over the next 5 to 10 years

10+ Years

Revitalized discovery efforts and increased expertise in biology to deliver ongoing scientific breakthroughs for decades to come

18

slide-19
SLIDE 19

Q&A

To ask a question on the operator-assisted audio line, press *1. Note: be sure to mute your computer speakers if you are listening to the audio webcast.

19